What does ivonib treat? How is the effect?

Ivosidenib is an IDH1 inhibitor indicated for the treatment of adults with acute myeloid leukemia (AML) and cholangiocarcinoma who have mutations in the isocitrate dehydrogenase-1 (IDH1) gene.

Avosidenib is suitable for the treatment of adult patients with IDH1mutated relapsed or refractory acute myeloid leukemia(AML), and is also suitable for patients aged ≥ Adults 75 years of age with newly diagnosed IDH1 mutated AML or with comorbidities that preclude the use of intensive induction chemotherapy with or without azacitidine. Acute myeloid leukemia is a blood cancer that causes an increase in the number of abnormal immature white blood cells (myeloblasts) in the blood and bone marrow. People with IDH1 mutations develop AML because it prevents myeloblasts from turning into healthy white blood cells (granulocytes). Ivonib is a targeted therapy that specifically targets IDH1 mutated cells and helps myeloblasts grow into healthy cells, about 6% Up to 10% of AML patients have IDH1 mutations.

Ivonib is indicated for the treatment of locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with susceptible IDH1 mutations, a rare and aggressive form of cholangiocarcinoma in which IDH1 mutations occur in up to 20% of cholangiocarcinoma cases.

Clinical research on ivonib shows that it can effectively prevent the growth and spread of cancer cells and improve patients' clinical symptoms and quality of life, with significant therapeutic effects. If you want to get more high-quality information, you can contact Yaode . Yaode will do its best to learn more about high-quality overseas drugs for you.